BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
BioVaxys Technology Corp (OTCQB: BVAXF) has announced significant study results for its DPX™ immune-educating delivery platform. The research, conducted with Dalhousie University, demonstrates that DPX outperforms traditional aqueous and emulsion-based antigen delivery systems in immune system activation. Key findings show that DPX maintains antigens at the injection site and drives active APC uptake over time. The platform demonstrated superior lymphocyte retention and significant immune cell infiltration within 2 days of injection. Notably, DPX showed activation of more critical T cell subset markers than oil emulsion systems and exhibited inherent immune-activating properties even without antigen cargo.
BioVaxys Technology Corp (OTCQB: BVAXF) ha annunciato risultati significativi per la sua piattaforma di somministrazione immuno-educativa DPX™. La ricerca, condotta con l'Università di Dalhousie, dimostra che DPX supera i tradizionali sistemi di somministrazione di antigeni a base acquosa ed emulsione in attivazione del sistema immunitario. Risultati chiave mostrano che DPX mantiene gli antigeni nel sito di iniezione e promuove l'assunzione attiva degli APC nel tempo. La piattaforma ha dimostrato una superiore ritenzione dei linfociti e una significativa infiltrazione di cellule immunitarie entro 2 giorni dall'iniezione. In particolare, DPX ha mostrato l'attivazione di marcatori di sottogruppi di cellule T più critici rispetto ai sistemi a emulsione oleosa e ha esibito proprietà intrinseche di attivazione immunitaria anche senza carico antigenico.
BioVaxys Technology Corp (OTCQB: BVAXF) ha anunciado resultados significativos para su plataforma de entrega inmuno-educativa DPX™. La investigación, realizada con la Universidad de Dalhousie, demuestra que DPX supera a los sistemas tradicionales de entrega de antígenos basados en agua y emulsiones en la activación del sistema inmunológico. Hallazgos clave muestran que DPX mantiene los antígenos en el sitio de inyección y promueve la captación activa de APC con el tiempo. La plataforma demostró una retención superior de linfocitos y una infiltración significativa de células inmunitarias en 2 días después de la inyección. Notablemente, DPX mostró la activación de marcadores de subgrupos críticos de células T en comparación con los sistemas de emulsión oleosa y exhibió propiedades inherentes de activación inmunitaria incluso sin carga de antígeno.
BioVaxys Technology Corp (OTCQB: BVAXF)가 자사의 면역 교육 전달 플랫폼인 DPX™에 대한 중요한 연구 결과를 발표했습니다. 달하우지 대학교와 함께 진행된 이 연구는 DPX가 전통적인 수용성 및 유화 기반 항원 전달 시스템보다 면역 시스템의 활성화에서 우수함을 보여줍니다. 주요 결과는 DPX가 주사 부위에서 항원을 유지하고 시간이 지남에 따라 활성 APC의 섭취를 유도한다는 것을 나타냅니다. 이 플랫폼은 주사 후 2일 이내에 림프구 유지와 면역 세포 침투가 뛰어났음을 입증했습니다. 특히, DPX는 오일 유화 시스템보다 더 중요한 T 세포 하위 군 분석의 활성화를 나타냈으며, 항원 화물 없이도 본래의 면역 활성화 특성을 보였습니다.
BioVaxys Technology Corp (OTCQB: BVAXF) a annoncé des résultats d'étude significatifs pour sa plateforme de livraison immuno-éducative DPX™. La recherche, réalisée avec l'Université de Dalhousie, démontre que DPX surpasse les systèmes de livraison d'antigènes à base d'eau et d'émulsion traditionnels en activation du système immunitaire. Résultats clés montrent que DPX maintient les antigènes sur le site d'injection et favorise l'absorption active des APC au fil du temps. La plateforme a démontré une rétention supérieure des lymphocytes et une infiltration significative des cellules immunitaires dans les 2 jours suivant l'injection. Notamment, DPX a montré l'activation de marqueurs de sous-ensembles critiques de cellules T par rapport aux systèmes à émulsion huileuse et a présenté des propriétés intrinsèques d'activation immunitaire même sans charge d'antigène.
BioVaxys Technology Corp (OTCQB: BVAXF) hat bedeutende Studienergebnisse für seine immun-educative Lieferplattform DPX™ bekannt gegeben. Die Forschung, die in Zusammenarbeit mit der Dalhousie Universität durchgeführt wurde, zeigt, dass DPX traditionelle wasser- und emulsionbasierte Antigendeliveriesysteme in der Aktivierung des Immunsystems übertrifft. Schlüsselbefunde zeigen, dass DPX die Antigene am Injektionsort hält und die aktive Aufnahme von APC im Laufe der Zeit fördert. Die Plattform zeigte eine überlegene Lymphozytenretention und signifikante Infiltration von Immunzellen innerhalb von 2 Tagen nach der Injektion. Bemerkenswert ist, dass DPX eine Aktivierung kritischer T-Zelluntergruppenmarker im Vergleich zu Ölemulsionssystemen zeigte und sogar ohne Antigenladung über eingebaute immunaktivierende Eigenschaften verfügte.
- DPX platform demonstrates superior immune activation compared to existing delivery systems
- Platform shows inherent immune-activating properties even without antigen cargo
- Technology targets segments of $270B+ drug delivery systems market
- Significant immune cell infiltration detected within 2 days of DPX injection
- None.
Study Results Position Company to Target Segments of
With cancer vaccines, the successful eradication of tumors relies on the persistent delivery of antigenic APCs to prime potent, antigen specific, cytotoxic T cells. Current peptide antigen delivery methods include using either water-based formulations which provide short exposure of peptides to immune cells, or oil-in-water emulsions that provide longer peptide exposure but that can elicit dysfunctional T cell phenotypes. In contrast, BioVaxys' DPX technology is a non-aqueous, lipid-in-oil, immune-educating therapeutic delivery platform that keeps the antigen cargo at the site of injection, ensuring that uptake of the DPX-encapsulated cargo is an active process driven by the APCs across time.
In a study done in collaboration with
"BioVaxys is at the forefront of a significant shift in the drug delivery landscape," James Passin, CEO of BioVaxys, stated, "These groundbreaking study results validate our strategic position in an important segment of the multi-billion drug delivery market. DPX not only outperforms current antigen delivery solutions but also demonstrate inherent immune-activating properties, opening up significant revenue potential across multiple market segments."
The study results showed that aqueous formulations were poorly able to retain lymphocytes at the injection site and consequently did not elicit a detectable IFN-γ ELISpot response. Both DPX and the oil emulsion were superior in recruiting APCs to the injection site and inducing antigen-specific immune responses, and with significant increases in immune cell infiltration detected as early as 2 days post DPX injection. However, a significant difference between DPX and oil emulsion was that antigen presentation driven by the DPX platform resulted in activation of more critical markers of T cell subsets than emulsion. An additional and highly significant finding is that recruitment and activation of these T cell subsets by DPX was evident regardless of whether an antigen was contained as cargo in DPX, indicating that DPX on its own has immune system activating properties.
Kenneth Kovan, President and Chief Operating Officer at BioVaxys, stated "We know that compared to DPX remaining at the injection site, emulsion-based and aqueous formulations leach cargo into surrounding tissues. These findings further highlight the quantitative, qualitative, and temporal differences in immune cell recruitment by DPX and two common delivery platforms and show the character of the immune response triggered by the DPX platform via activation of T cell subsets with intrinsically higher capacity for antigen uptake, presentation, and activation."
BioVaxys is planning to present additional data in early December on the unique characteristics of DPX
1Drug Delivery Devices Market Size, Share & Trends Analysis Report By Application (Oncology, Infectious Diseases), By Route Of Administration (Oral, Transdermal, Injectable), By End-use, By Region, And Segment Forecasts, 2024 – 2030, Grand View Research
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© "neoantigen" tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +740 358 0555
Email: jpassin@biovaxys.com
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Logo - https://mma.prnewswire.com/media/2415135/4999130/BioVaxys_Technology_Corp_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biovaxys-dpx-exhibits-superior-immune-system-activation-compared-to-aqueous-and-emulsion-based-antigen-delivery-systems-302292183.html
SOURCE BioVaxys Technology Corp.
FAQ
What are the key advantages of BioVaxys' (BVAXF) DPX delivery platform?
How does BioVaxys' (BVAXF) DPX platform compare to aqueous formulations?
What market opportunity is BioVaxys (BVAXF) targeting with its DPX platform?
